Scott P A, Chou J M, Tang H, Frazer A
Neuropsychopharmacology Unit, Department of Veterans Affairs Medical Center, Philadelphia, Pennsylvania.
J Pharmacol Exp Ther. 1994 Jul;270(1):198-208.
In the rat, activation of 5-hydroxytryptamine1A (5-HT1A) receptors causes hypothermia and the 5-HT syndrome. The effects of three chemically dissimilar 5-HT1A agonists administered s.c. [8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), gepirone, and (+)4-[n-5-(methoxychroman-3-yl)n-propylamino]butyl-8-azaspiro++ +[4,5] decane-7,adione ((+) S-20499)] on both of these responses were studied. The same maximal drop in body temperature (approximately 2.5 degrees C) was elicited by all three agonists, 8-OH-DPAT being the most potent (EC50 = 0.05 mg/kg), followed by gepirone (1.8 mg/kg) and (+) S-20499 (8 mg/kg). Both pindolol, a nonselective 5-HT1A receptor/beta adrenoceptor antagonist and n-t-butyl,-3-[1-[4-(2-methoxy)phenyl]piperazinyl]-1-phenylpropionamid e [(+) WAY 100135], a more selective 5-HT1A receptor antagonist, dose dependently attenuated the hypothermia induced by all three agonists. From these data, we inferred that all three agonists caused hypothermia via activation of 5-HT1A receptors. The syndrome was observed reliably in rats at doses of 2 to 4 mg/kg 8-OH-DPAT; doses up to 100 mg/kg of gepirone or (+) S-20499 did not produce the syndrome. In reserpine-pretreated animals, 8-OH-DPAT (maximal effect at 2-4 mg/kg) and 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) (5 mg/kg) induced forepaw treading, whereas gepirone (10 mg/kg) and (+) S-20499 (75 mg/kg) did not. (+) WAY 100135 competitively antagonized the forepaw treading caused by 8-OH-DPAT in reserpine-pretreated rats. This indicates that forepaw treading, like hypothermia, is mediated by activation of 5-HT1A receptors. Gepirone (5-10 mg/kg) attenuated the forepaw treading induced by either 8-OH-DPAT (4 mg/kg) or 5-MeODMT (5 mg/kg); by contrast, (+) S-20499, at doses up to 75 mg/kg, did not attenuate the forepaw treading induced by either 8-OH-DPAT or 5-MeODMT. The inability of (+) S-20499 either to induce the 5-HT syndrome or forepaw treading or to attenuate the forepaw treading induced by other agonists could be due to several factors, one of which is that different subtypes of the 5-HT1A receptor mediate hypothermia and the 5-HT syndrome.
在大鼠中,5-羟色胺1A(5-HT1A)受体的激活会导致体温过低和5-羟色胺综合征。研究了三种化学结构不同的5-HT1A激动剂经皮下给药[8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)、吉哌隆和(+)4-[n-5-(甲氧基苯并二氢吡喃-3-基)正丙基氨基]丁基-8-氮杂螺[4,5]癸烷-7,9-二酮((+)S-20499)]对这两种反应的影响。所有三种激动剂均引起相同的最大体温下降(约2.5摄氏度),8-OH-DPAT最为有效(半数有效浓度(EC50)=0.05毫克/千克),其次是吉哌隆(1.8毫克/千克)和(+)S-20499(8毫克/千克)。吲哚洛尔是一种非选择性5-HT1A受体/β肾上腺素能受体拮抗剂,n-叔丁基-3-[1-[4-(2-甲氧基)苯基]哌嗪基]-1-苯基丙酰胺[(+)WAY 100135]是一种更具选择性的5-HT1A受体拮抗剂,二者均剂量依赖性地减弱了所有三种激动剂诱导的体温过低。根据这些数据,我们推断所有三种激动剂均通过激活5-HT1A受体导致体温过低。在大鼠中,剂量为2至4毫克/千克的8-OH-DPAT可可靠地观察到该综合征;剂量高达100毫克/千克的吉哌隆或(+)S-20499未产生该综合征。在利血平预处理的动物中,8-OH-DPAT(2至4毫克/千克时产生最大效应)和5-甲氧基-N,N-二甲基色胺(5-MeODMT)(5毫克/千克)诱导前爪踏地,而吉哌隆(10毫克/千克)和(+)S-20499(75毫克/千克)则不会。(+)WAY 100135竞争性拮抗利血平预处理大鼠中8-OH-DPAT引起的前爪踏地。这表明前爪踏地与体温过低一样,是由5-HT1A受体的激活介导的。吉哌隆(5至10毫克/千克)减弱了由8-OH-DPAT(4毫克/千克)或5-MeODMT(5毫克/千克)诱导的前爪踏地;相比之下,剂量高达75毫克/千克的(+)S-20499并未减弱由8-OH-DPAT或5-MeODMT诱导的前爪踏地。(+)S-20499既不能诱导5-羟色胺综合征或前爪踏地,也不能减弱其他激动剂诱导的前爪踏地,可能是由于多种因素,其中之一是5-HT1A受体的不同亚型介导体温过低和5-羟色胺综合征。